Date: October 26, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CEST) Current protein biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury...
Date: November 01, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 6:00pm (CET) Our laboratory developed the Pig-a gene mutation assay as a means to simply and reliably evaluate the potential mutage...
DATE: June 28, 2018TIME: 8:00AM PDTEnrichment of leukocytes from blood products like buffy coat, leukocyte reduction chambers (LRSC) or leukapheresis material can be time consuming...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Over the past decade, there has been a rapid growth in studies of secreted membrane vesicles, collectively called extracellular vesicles (EVs). (1) The release of EVs has been reported in the...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Date: October 26, 2022 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CEST) Current protein biomarkers are only moderately predictive in identifying individuals with mild traumatic brain injury...
Date: November 01, 2022 Time: 10:00am (PDT), 1:00pm (EDT), 6:00pm (CET) Our laboratory developed the Pig-a gene mutation assay as a means to simply and reliably evaluate the potential mutage...
DATE: June 28, 2018TIME: 8:00AM PDTEnrichment of leukocytes from blood products like buffy coat, leukocyte reduction chambers (LRSC) or leukapheresis material can be time consuming...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
Over the past decade, there has been a rapid growth in studies of secreted membrane vesicles, collectively called extracellular vesicles (EVs). (1) The release of EVs has been reported in the...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...